about
Effect of copper on extracellular levels of key pro-inflammatory molecules in hypothalamic GN11 and primary neurons.Inhibition of lactate dehydrogenase activity as an approach to cancer therapy.NAD metabolism and functions: a common therapeutic target for neoplastic, metabolic and neurodegenerative diseases.Albumin-drug conjugates in the treatment of hepatic disorders.Lactate dehydrogenase inhibition: exploring possible applications beyond cancer treatment.Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors.Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes.Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1.Lactate dehydrogenase inhibitors can reverse inflammation induced changes in colon cancer cells.Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase.Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells.Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.Impairment of aerobic glycolysis by inhibitors of lactic dehydrogenase hinders the growth of human hepatocellular carcinoma cell lines.Altered glycosylation profile of purified plasma ACT from Alzheimer's diseaseCharacterisation of the conjugate of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin with lactosaminated human albumin by 13C NMR spectroscopy.Synthesis of natural urolithin M6, a galloflavin mimetic, as a potential inhibitor of lactate dehydrogenase A.
P50
Q33487523-B566D4D0-535E-4A3F-B435-D7A61A2254A5Q35122361-D0F0FC1E-443E-49C2-B6D7-820E47FE4DF6Q38156476-F7D29D64-03C5-44F3-95D6-2EB5892B8541Q38207699-0888ED29-2A64-4C3E-AA8F-8C5A3596E756Q38800732-39C33A76-8C27-4C46-B948-DF8DCCB85AF6Q38859786-8B737100-31B8-4BDC-918D-D782E686289BQ38880369-8B43683A-D495-4261-9AC8-EC5B2B79DC5EQ39135553-F78A21D9-BFB4-4155-B4DF-114517C96ADBQ39396436-3D5C74FD-8F1A-4F56-B019-19D46D96032DQ39448204-89358218-EF90-4FA6-B826-138C49FED977Q39472703-A6D4D186-616C-4543-AABF-AF41C0E2F37DQ39618478-C0A8B12B-94E9-4F22-9115-DC3A7674E267Q39668830-0813BBFE-6CAB-49A6-8313-4E2FA9710F16Q42577150-63CB7A67-D5A7-4248-B4EE-F44A6F0DD67CQ43288857-2D3A2F37-AA03-460A-93F6-2C46F947257DQ48053265-142DC903-4D13-4EE3-BFB6-E9F0EA71E532
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marcella Manerba
@ast
Marcella Manerba
@en
Marcella Manerba
@es
Marcella Manerba
@nl
type
label
Marcella Manerba
@ast
Marcella Manerba
@en
Marcella Manerba
@es
Marcella Manerba
@nl
prefLabel
Marcella Manerba
@ast
Marcella Manerba
@en
Marcella Manerba
@es
Marcella Manerba
@nl
P106
P21
P31
P496
0000-0002-6860-0016